Becker Muscular Dystrophy
51
5
8
29
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Published Results
11 trials with published results (22%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
5.9%
3 terminated out of 51 trials
90.6%
+4.1% vs benchmark
6%
3 trials in Phase 3/4
38%
11 of 29 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 29 completed trials
Clinical Trials (51)
Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy
Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)
Registry for Duchenne and Becker Muscular Dystrophy
Multiparametric Ultrafast Ultrasound Biomarkers for Duchenne and Becker Muscular Dystrophies
Biomarker Development for Muscular Dystrophies
Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy
A Study to Assess Vamorolone in Becker Muscular Dystrophy (BMD)
A Study of EDG-5506 in Adult Males With Becker Muscular Dystrophy
Defining Endpoints in Becker Muscular Dystrophy
Follow-up Study on Female Carriers With DMD Gene Variants
Muscle MRI Outlining of Neuromuscular Diseases Using Artificial Intelligence
Effectiveness of 5-week Digital Respiratory Practice in Children With Duchenne and Becker Muscular Dystrophies.
UTSW HP [13-C] Pyruvate Injection in HCM
The Duchenne Registry
Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Becker Muscular Dystrophy
Characterization of Clinical Skeletal and Cardiac Impairment in Carriers of DMD and BMD
CureDuchenne Link®: A Resource for Research
Applying the Pathways and Resources for Engagement and Participation Protocol Among People With Muscles Dystrophies
Brain Involvement in Dystrophinopathies Part 1
Brain Involvement in Dystrophinopathies Part 2